Endonovo Evaluating Therapeutic Potential Of Non-Invasive Electroceutical Device Following Myocardial Infarction

LOS ANGELES, CA--(Marketwired - December 19, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, today announced it is commencing a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in the prevention of heart failure following myocardial infarction (MI). The pre-clinical study will evaluate the effect of the Company's non-invasive electroceutical technology on cardiac function, post-MI remodeling, and infarct size, as well as angiogenesis (the development of new blood vessels). The study, estimated to be complete at the end of the first quarter of 2017, represents the first of several planned studies designed to evaluate the Company's proprietary non-invasive electroceuticals in the treatment of vascular diseases and ischemia/reperfusion injury.

"We are leveraging the experience and proprietary knowledge of our scientific team, which has undertaken over 25 years of research and development in the field of bioelectromagnetic therapeutics in angiogenesis, neuroinflammation and ischemia to develop non-invasive treatments for substantially unmet clinical needs," commented Endonovo Chairman and CEO, Alan Collier.

"A positive result in this study would represent a significant milestone for Endonovo and the field of bioelectronic medicine. We are moving to establish Endonovo as the leader in electroceuticals-based regenerative medicine. Our competitors in the bioelectronic medicine space are primarily developing implantable devices targeting the inflammatory response, and our competitors in regenerative medicine are developing cell therapies, biologics and gene therapies to treat many of these diseases, which are more expensive to develop and present significantly more safety concerns for potential patients.

"Our technology presents a lucrative opportunity to develop a non-invasive platform device that can be used to treat cardiovascular, cerebrovascular and peripheral artery disease as well as ischemia/reperfusion injuries," concluded Mr. Collier.

The Company had previously announced receiving a term sheet for $5 million in preferred financing from a strategic healthcare investor to develop a pipeline in vascular diseases, peripheral artery disease and ischemia/reperfusion injury. The $5 million proposed financing is part of a larger $15 million round of financing to uplist the Company's common stock onto a national stock exchange in the first half of 2017.

About Heart Disease

Coronary artery disease (CAD) is the leading cause of death in the United States, with approximately 500,000 to 700,000 deaths related to CAD occurring each year.

In the United States, approximately 1.1 million cases of myocardial infarction (MI) occur annually, according to the American Heart Associations' Heart Disease and Stroke Statistics -- 2016 Update. MI is a condition where myocardial ischemia, a diminished blood supply to the heart, exceeds a critical threshold and overwhelms myocardial cellular repair mechanisms designed to maintain normal operating function and homeostasis. Ischemia at this critical threshold level for an extended period results in irreversible myocardial cell damage or death, and can result in heart failure.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a leading developer of bioelectronic-applications in cell therapies and non-invasive electroceuticals. Endonovo's Immunotronics™ platform is dedicated to treating patients with life-threatening inflammatory conditions in vital organs using proprietary non-invasive electroceutical devices. The Company's non-invasive platform is based on magnetically-induced electrical field pathways that target the disruption of inflammation and cell death.

The Company's Cytotronics™ platform harnesses the bulk electrical properties of cells and tissues, namely magnetically-induced electrical field pathways to expand and enhance the therapeutic potential of cell therapies and produce next-generation biologics.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investors: Sign Up for Email Alerts on Endonovo